Customized Pharmacokinetics Studies with Knockout Rat Models
News Jul 03, 2012
NoAb BioDiscoveries, in collaboration with SAGE Labs, is introducing the use of SAGE™ knockout rats with its tools to investigate the Blood Brain Barrier including micro dialysis and serial CSF collection, as a service to drug discovery researchers.
Rats provided by SAGE (Sigma Advanced Genetic Engineering) Labs are available with knockouts of the specific drug transporter genes Mdr1a, Mrp1, Mrp2, Bcrp, or Oct1.
These advanced animal models are designed to study and characterize the drug-like properties of compounds in vivo.
Dan Lichtman, President and CEO of NoAb BioDiscoveries, said “This partnership with SAGE Labs strengthens our service offering in drug discovery research. Preclinical researchers will benefit from the combined expertise and leadership of NoAb and SAGE.”
NoAb BioDiscoveries is a preclinical Contract Research Organization that offers a wide range ADME-PK Discovery services, specializing in in vivo models, in vitro assays and bioanalytical support.
In addition to standard drug disposition studies, specific surgical catheterization points available at NoAb BioDiscoveries include Jugular Vein, Carotid Artery, Hepatoportal Vein, Bile Duct, and Intestinal Subsections.
Such customized models form an important component of the tools that an investigator can use to address unique and specific questions about their compounds.
Multidisciplinary Study Suggests New Strategy for Drug DiscoveryNews
A joint industry/academia study of a cancer target protein reveals unusual relation between binding site flexibility and drug-target lifetime. The results, , suggest a new strategy for drug discovery.READ MORE
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE